Recent investigations suggest an interdependence between blood fluidity and walking performance in patients with peripheral arterial occlusive disease (PAOD). Therefore, various blood fluidity variables (erythrocyte aggregation, erythrocyte flexibility, plasma viscosity, plasma proteins) were studied in groups of healthy subjects and claudicants with severe PAOD (exhausted perfusion re serve) receiving intravenous treatment with Trental (600 mg Pentoxifylline b.i.d., 21 days).
Erythrocyte flexibility (expressed by filterability through micropore filters), red cell aggregation and plasma viscosity deteriorate with progression of disease especially in Stage IIb and III Fontaine classification, with walking distance below 150 m.
Trental treatment resulted in patients with advanced POAD stages in im provement of red cell filterability, red cell aggregation, decrease of plasma vis cosity, increase in absolute walking distance and relief from rest pain, suggesting that such patients are accessible to conservative treatment with he morheologically active agents.
Get full access to this article
View all access options for this article.
References
1.
Angelkort B. , Kiesewetter H.: Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease. Scand J Clin Lab Invest41(156): 185, 1981 .
2.
Angelkort B. , Pirnay D., Kiesewetter H., Maurin N.: Hemodilution and Pentoxifylline effects on muscle blood flow and blood fluidity in chronic occlusive arterial disease . Vasc Med1: 150, 1983.
3.
Dintenfass L.: Rheology of blood in diagnostic and preventive medicine. London, Boston, Butterworth , 1976.
4.
Gaillard S., Schooneman E., Voisin P., et al: Effets comparés sur la filtrabilité in vivo chez l'homme de deux formes galéniques de la Pentoxifylline. Ann MedNancy105: 150, 1979.
5.
Leonhardt H. , Arntz HR: Zusammenhänge zwischen kardiovaskulären Risikofaktoren und der Blutviskosität unter besonderer Berücksichtigung der Hyperlipoproteinämien . Rheol Acta16: 360, 1977.
6.
Lowe Gdo, et al: Double-blind controlled clinical trial of ancrod in the relief of ischaemic rest pain of the leg. Angiology33: 46, 1982.
7.
Martin M., et al: Defibrinogenation treatment in patients suffering from severe intermittent claudication-a controlled study. Thrombosis Research USA9: 47, 1976.
8.
Müller R.: Pentoxifylline: a biochemical profile. J Med10: 307, 1979.
9.
Reid HL, Dormandy JA, Barnes AJ: Impaired red cell-deformability in peripheral vascular disease. LancetI: 666, 1976.
10.
Schmid-Schönbein H., Rieger H., Fischer T.: Blood fluidity as a consequence of red cell fluidity: flow properties of blood and flow behaviour of blood in vascular diseases. 1980.
11.
Swislocki NI , Kramer JJ, O'Connell, MA Cunningham EB: Covalent modification of membrane components in the regulation of erythrocyte shape. Annals NY AcademySciences416: 662, 1983.
